Wyeth

Twi Biotechnology, Inc.

National Taiwan University

National Cheng-kung University

Wyeth Holdings Corporation

Savior Lifetec Corporation

Mannching Sherry Ku

Anthony Francis Hadfield

Warren Chew

Mahmoud Mirmehrabi

Gloria Cheal

Marc Sadler Tesconi

Qinghong Lu

Wei-Shu Lu

I-Yin Lin, Iii

Yan Xu

Chih-Ming Chen

Chih-Kuang Chen

Quinhong Lu

Silvio Iera

David Michael Blum

Yanzhong Wu

Lalitha Krishnan

Subodh S Deshmukh

Woei-Jer Chuang

Wen-Mei Fu

Hong Wen

Abdolsamad Tadayon

Yen-Lun Huang

Danchen Gao

Fang Fang Qi

Shih-Hsie Pan

W James Huang

Anthony Hadfield

James W Huang

Anthony F Hadfield

Gloria Karen Cheal

Qinhong Lu

I-Yin Lin

Chia-Hsin Lin

Yan-Ming Chen

The present invention relates to maleate salt forms of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide, methods of preparing crystalline maleate salt forms, the associated compounds, and pharmaceutical compositions containing the same. The maleate salts are useful in treating cancers, particularly those affected by kinases of the epidermal growth factor receptor family.

Maleate salts of (E)-N-{4[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof

Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof

Maleate salts of (E)-N-{4-[3-Chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof

Methods and compositions for treating and/or preventing hyperuricemia or metabolic disorders associated with hyperuricemia comprising administering to a patient in need a therapeutically effective amount of diacerein, rhein, or a pharmaceutically acceptable salt, an analog, a prodrug, or an active metabolite thereof.

Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia

Methods for treating abnormal glycosylated hemoglobin (HbA1c) levels in a patient in need thereof, wherein the provided methods comprise administering to a patient in need a therapeutically effective amount of an Interleukin-1&#x3b2; modulator. Also, the invention provides compositions comprising at least one lipid modifying agent and an IL-1&#x3b2; modulator.

Methods of decreasing glycosylated hemoglobin in patients with dyslipidemia

The present invention provides methods of treating type II diabetes using combinations of diacerein or its derivatives with other antidiabetic agents. The methods may also allow improving glycemic control of type II diabetes patients and/or reducing side effects and/or cardiovascular risks of antidiabetic agents.

Methods of using diacerein as an adjunctive therapy for diabetes

Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-2-buteramide and crystalline forms thereof

Crystalline solid forms of tigecycline, Form I, Form II, Form III, Form IV, and Form V, compositions comprising these crystalline solid forms, and processes for preparing these crystalline solid forms are described herein.

Crystalline solid forms of tigecycline and methods of preparing same

The invention provides disintegrin variants, and more specifically to disintegrin variants which are selective &#x3b1;v&#x3b2;3 integrin antagonists for treatment and prevention of &#x3b1;v&#x3b2;3 integrin-associated diseases. The present invention also relates to pegylated proteins, including proteins comprising a disintegrin variant having an RGD motif variantARLDDL. The invention also relates to the use of the polypeptides of the invention for the treatment and prevention of &#x3b1;v&#x3b2;3 integrin-associated diseases.

Methods of treating &#x3b1;v&#x3b2;3 integrin-associated diseases by administering polypeptides selective for &#x3b1;v&#x3b2;3 integrin

Tanaproget polymorph Form II, processes for preparing tanaproget polymorph Form II, pharmaceutical compositions including tanaproget polymorph Form II, micronized tanaproget polymorph Form II, and processes for converting Form II to tanaproget Form I are provided. Also provided are methods of contraception, hormone replacement therapy, stimulation of food intake and treating or preventing uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, or carcinomas and adenocarcinomas comprising administering polymorph Form II to a mammalian subject.

Polymorph form II of tanaproget

Process for preparing polymorph form II of tanaproget

The present invention is directed to monohydrate and anhydrate crystal forms of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol, an estrogenic receptor modulator useful in the treatment of, for example, diseases related to abnormal levels of estrogen.

Crystal forms of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol

Growing community of inventors

Thiells, NY, United States of America

Mannching Sherry Ku